MedTrace Logo

Whey Protein Supplementation and Serum Mineral Status in Elite Endurance and Power Athletes

NCT07488273 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2026-03-24

No results posted yet for this study

Summary

This study investigates whether 8 weeks of post-training whey protein supplementation (30 g/day) affects serum mineral concentrations (calcium, phosphorus, magnesium, and iron) in elite endurance and power athletes during structured training.

Conditions

  • Athletic Performance

Interventions

DIETARY_SUPPLEMENT

Whey Protein Supplementation

Participants in the intervention group consumed 30 g/day of whey protein powder within 30 minutes after training sessions for 8 weeks as part of a structured training program. The supplement (IronMaxx®, 100% Whey Protein) primarily consisted of whey protein concentrate and provided approximately 24 g of protein per daily dose. The intervention was administered in an open-label manner without placebo control. Participants were instructed to maintain their habitual diet and refrain from using additional nutritional supplements during the study period.

OTHER

No Supplement (Control)

Participants continued their usual sport-specific training program for 8 weeks without receiving whey protein or any additional nutritional supplementation. They were instructed to maintain their habitual diet and avoid initiating any new supplements during the study period.

Sponsors & Collaborators

  • Monira Aldhahi

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-25
Primary Completion
2026-02-26
Completion
2026-03-15

Countries

  • Tunisia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07488273 on ClinicalTrials.gov